William F. Doyle's most recent trade in ProKidney Corp - Ordinary Shares - Class A was a trade of 135,000 Director stock option (right to buy) done . Disclosure was reported to the exchange on May 28, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ProKidney Corp Ordinary | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 135,000 | 135,000 | - | - | Director stock option (right to buy) | |
| ProKidney Corp Ordinary | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 125,862 | 125,862 | - | - | Director stock option (right to buy) | |
| Elanco Animal Health Inc | William F. Doyle | Director | 29 Nov 2024 | 18,169 | 94,499 (0%) | 0% | 0 | Common Stock | ||
| ProKidney Corp Ordinary | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 62,558 | 62,558 | - | - | Director stock option (right to buy) | |
| Elanco Animal Health Inc | William F. Doyle | Director | 21 May 2024 | 15,000 | 76,330 (0%) | 0% | 17.0 | 254,700 | Common Stock | |
| Elanco Animal Health Inc | William F. Doyle | Director | 08 Mar 2024 | 15,000 | 61,330 (0%) | 0% | 16.3 | 244,500 | Common Stock | |
| Elanco Animal Health Inc | F. Doyle William | Director | 30 Nov 2023 | 20,374 | 46,330 (0%) | 0% | 0 | Common Stock | ||
| ProKidney Corp Ordinary | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 48,128 | 48,128 | - | - | Director Stock Option (right to buy) | |
| Elanco Animal Health Inc | William F. Doyle | Director | 30 Nov 2022 | 18,649 | 25,956 (0%) | 0% | 0 | Common Stock | ||
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 69.66 per share. | 02 Aug 2022 | 837 | 551,176 (0%) | 0% | 69.7 | 58,305 | Ordinary Shares |
| ProKidney Corp Ordinary | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 1,514,326 | 1,514,326 | - | - | Class B Ordinary Shares | |
| ProKidney Corp Ordinary | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 1,514,326 | 1,514,326 | - | - | Common Units in ProKidney LP | |
| Minerva Neurosciences Inc | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 2,500 | 2,500 | - | - | Stock Option (right to buy) | |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 70.10 per share. | 08 Mar 2022 | 2,385 | 552,013 (0%) | 0% | 70.1 | 167,189 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 14,581 | 14,581 | - | - | Options to Buy Ordinary Shares | |
| Elanco Animal Health Inc | William F. Doyle | Director | 30 Nov 2021 | 7,307 | 7,307 (0%) | 0% | 0 | Common Stock | ||
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 149.38 per share. | 02 Aug 2021 | 995 | 554,398 (0%) | 0% | 149.4 | 148,631 | Ordinary Shares |